此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Penpulimab联合化疗用于可切除HNSCC患者的新辅助和辅助治疗

Penpulimab联合化疗用于可切除头颈鳞状细胞癌新辅助及辅助治疗的II期临床研究

This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.

研究概览

研究类型

介入性

注册 (估计的)

72

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200011
        • Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients voluntarily joined the study, signed the informed consent, and had good compliance;
  • Patients with 18 Years to 75 Years(at the time of signing the informed consent); Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score: 0-1;
  • Patients with untreated head and neck squamous cell carcinoma who were pathologically confirmed and determined to be suitable for surgical treatment were classified as stage III, IVa according to AJCC (8th Edition), including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers
  • Female patients of reproductive age should agree that birth control (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; Having a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study.

Exclusion Criteria:

  • Patients who have previously used PD-1/PD-L1/CTLA-4 antibody therapy;
  • Patients who require systemic treatment with corticosteroids (> 10mg daily prednisone equivalent) or other immunosuppressive drugs within 14 days prior to administration or during treatmentIn the absence of active autoimmune disease, inhaled or topical steroids and adrenocortical hormone at doses >10mg/ day equivalent to prednisone and adrenocortical hormone replacement at therapeutic doses not exceeding 10mg/ day prednisone are permitted;
  • A history of any active immune or autoimmune disease, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
  • Active or uncontrolled severe infection within 4 weeks prior to enrollment (CTCAE grade 2 infection);
  • Abnormal function of major organs
  • Patients with concomitant diseases that, in the investigator's judgment, may seriously endanger patients' safety or may interfere with the completion of the study, or are deemed unsuitable for inclusion for other reasons.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Penpulimab combined with cisplatin and albumin-paclitaxel neoadjuvant therapy

Penpulimab injection combined with cis-platinum and albumin-bound paclitaxel before surgery, 21 days as a treatment cycle.

Adjuvant therapy was started within 6 weeks after surgery:Patients who achieved MPR after surgery were randomized 1:1 with standard adjuvant therapy(RT alone or combined with cisplatin) and Alternative adjuvant therapy(RT alone or combined with Penpulimab).

Non-MPR patients receive standard adjuvant therapy

Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2); 200mg,D1, IV(21 days/cycle).

Cisplatin :75mg/m2, D1, IV(21 days/cycle)

albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Major pathological response(MPR)
大体时间:One year

Major pathologic response is based on the pathological examination on the post-operative specimens.

One year

次要结果测量

结果测量
措施说明
大体时间
Disease-control Rate(DCR)
大体时间:Baseline up to 3 years.

The proportion of subjects response of CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥4 weeks).

Baseline up to 3 years.
Adverse event rate
大体时间:Baseline up to 3 years.

The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

Baseline up to 3 years.
Disease-free survival at 2 years(DFS at 2 years)
大体时间:Baseline up to 2 years.

The proportion of subjects disease-free survival at 2 years

Baseline up to 2 years.
Overall Response Rate (ORR)
大体时间:Baseline up to 3 years.

The proportion of subjects who achieves a best overall response of CR or PR.

Baseline up to 3 years.
Local recurrence-free survival at 2years(LRFS at 2 years)
大体时间:Baseline up to 2 years.

The proportion of subjects local recurrence-free survival at 2years

Baseline up to 2 years.
distant metastasis-free survival at 2 years(DMFS at 2 years)
大体时间:Baseline up to 2 years.

The proportion of subjects distant metastasis-free survival at 2years

Baseline up to 2 years.
OS at 2 years
大体时间:Baseline up to 2 years.

The overall survival time refers to the time from initiating inductive therapy to death due to any cause.

Baseline up to 2 years.
pathologic complete response(pCR)
大体时间:One year

Pathological examination showed the presence of 0% active tumor in the tissue specimen

One year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年10月17日

初级完成 (估计的)

2026年12月30日

研究完成 (估计的)

2027年10月30日

研究注册日期

首次提交

2023年9月25日

首先提交符合 QC 标准的

2023年10月7日

首次发布 (实际的)

2023年10月13日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅